Matthias Stoll
Overview
Explore the profile of Matthias Stoll including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
54
Citations
732
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Schmidt D, Kollan C, Stoll M
Front Public Health
. 2024 Jun;
12:1404255.
PMID: 38873299
Background: In Europe, the combination of cabotegravir (CAB) with rilpivirine (RPV) has been approved as a dual injection long-acting (LA) therapy for the treatment of human immunodeficiency virus type 1...
2.
Stecher M, Schommers P, Kollan C, Stoll M, Kuhlendahl F, Stellbrink H, et al.
Infection
. 2021 Aug;
49(6):1365-1366.
PMID: 34346028
No abstract available.
3.
Swindells S, Lutz T, Van Zyl L, Porteiro N, Stoll M, Mitha E, et al.
AIDS
. 2021 Jul;
36(2):185-194.
PMID: 34261093
Background: ATLAS (NCT02951052), a phase 3, multicenter, open-label study, demonstrated that switching to injectable cabotegravir (CAB) with rilpivirine (RPV) long-acting dosed every 4 weeks was noninferior at week (W) 48...
4.
Sandmann L, Stoll M, Behrens G
AIDS
. 2021 Apr;
35(9):1516-1518.
PMID: 33831912
Treatment with tenofovir disoproxil fumarate (TDF) has been associated with hypophosphatemia mainly because of injury of the renal proximal tubulus. Studies on the impact of tenfovir alafenamide (TAF) on phosphate...
5.
Schmidt D, Kollan C, Stoll M, Hamouda O, Bremer V, Kurth T, et al.
BMC Public Health
. 2021 Jan;
21(1):200.
PMID: 33482773
Background: The aim of this study was to develop a standardized method to reconstruct persons' individual viral load (VL) courses to determine viral suppression and duration of viremia for the...
6.
Ahrenstorf G, Jablonka A, Ernst D, Bange F, Heiken H, Witte T, et al.
J Acquir Immune Defic Syndr
. 2020 Sep;
86(1):e9-e12.
PMID: 32947445
No abstract available.
7.
Joean O, Thiele T, Schutz K, Schwerk N, Sedlacek L, Kalsdorf B, et al.
BMC Infect Dis
. 2020 Sep;
20(1):678.
PMID: 32942990
Background: Tuberculosis (TB) control is a primary global health priority but the goal to eliminate TB is being threatened by the increase in incidence of multidrug-resistant tuberculosis (MDR-TB). With this...
8.
Odak I, Barros-Martins J, Bosnjak B, Stahl K, David S, Wiesner O, et al.
EBioMedicine
. 2020 Jul;
57:102885.
PMID: 32650275
Background: Elucidating the role of T cell responses in COVID-19 is of utmost importance to understand the clearance of SARS-CoV-2 infection. Methods: 30 hospitalized COVID-19 patients and 60 age- and...
9.
Stecher M, Schommers P, Kollan C, Stoll M, Kuhlendahl F, Stellbrink H, et al.
Infection
. 2020 Jul;
48(5):723-733.
PMID: 32613529
Objective: Combination antiretroviral therapy (cART) has markedly increased survival and quality of life in people living with HIV. With the advent of new treatment options, including single-tablet regimens, durability and...
10.
Mohn N, Saker F, Bonda V, Respondek G, Bachmann M, Stoll M, et al.
J Neurol
. 2020 Jun;
267(10):2803-2805.
PMID: 32494855
No abstract available.